Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Revenio Group Oyj

BATS-CHIXE:REG1VH
Snowflake Description

High growth potential with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
REG1VH
BATS-CHIXE
€608M
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Revenio Group Oyj, a health technology company, designs, manufactures, and sells medical instruments for the early detection of glaucoma, diabetic retinopathy, and macular degeneration in Finland, Italy, rest of Europe, the United States, and internationally. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • Revenio Group Oyj has significant price volatility in the past 3 months.
REG1VH Share Price and Events
7 Day Returns
0.7%
BATS-CHIXE:REG1VH
-1.2%
GB Medical Equipment
0.1%
GB Market
1 Year Returns
37.6%
BATS-CHIXE:REG1VH
-0.3%
GB Medical Equipment
-23.6%
GB Market
REG1VH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Revenio Group Oyj (REG1VH) 0.7% -13.3% -8.6% 37.6% 92.1% 246.8%
GB Medical Equipment -1.2% -12% -19.1% -0.3% -2.3% 20.9%
GB Market 0.1% -15.5% -27% -23.6% -24.3% -23.5%
1 Year Return vs Industry and Market
  • REG1VH outperformed the Medical Equipment industry which returned -0.3% over the past year.
  • REG1VH outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23.6% over the past year.
Price Volatility
REG1VH
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Revenio Group Oyj undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Revenio Group Oyj to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Revenio Group Oyj.

BATS-CHIXE:REG1VH Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.8%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:REG1VH
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 5.9%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.81
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.808 (1 + (1- 20%) (4.74%))
0.892
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.89
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (0.892 * 5.94%)
5.83%

Discounted Cash Flow Calculation for BATS-CHIXE:REG1VH using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Revenio Group Oyj is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:REG1VH DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 5.83%)
2020 12.25 Analyst x2 11.58
2021 19.20 Analyst x2 17.14
2022 23.45 Analyst x2 19.79
2023 27.55 Analyst x2 21.97
2024 32.05 Analyst x2 24.15
2025 35.21 Est @ 9.86% 25.07
2026 37.70 Est @ 7.06% 25.36
2027 39.62 Est @ 5.1% 25.19
2028 41.10 Est @ 3.73% 24.69
2029 42.24 Est @ 2.77% 23.98
Present value of next 10 years cash flows €218.00
BATS-CHIXE:REG1VH DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €42.24 × (1 + 0.53%) ÷ (5.83% – 0.53%)
€801.71
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €801.71 ÷ (1 + 5.83%)10
€455.06
BATS-CHIXE:REG1VH Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €218.00 + €455.06
€673.06
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €673.06 / 26.45
€25.45
BATS-CHIXE:REG1VH Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:REG1VH represents 0.99565x of HLSE:REG1V
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.99565x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 25.45 x 0.99565
€25.34
Value per share (EUR) From above. €25.34
Current discount Discount to share price of €22.90
= -1 x (€22.90 - €25.34) / €25.34
9.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Revenio Group Oyj is available for.
Intrinsic value
10%
Share price is €22.9 vs Future cash flow value of €25.34
Current Discount Checks
For Revenio Group Oyj to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Revenio Group Oyj's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Revenio Group Oyj's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Revenio Group Oyj's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Revenio Group Oyj's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:REG1VH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €0.36
HLSE:REG1V Share Price ** HLSE (2020-04-07) in EUR €23
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 25.55x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 748 Publicly-Listed Companies 12.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Revenio Group Oyj.

BATS-CHIXE:REG1VH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= HLSE:REG1V Share Price ÷ EPS (both in EUR)

= 23 ÷ 0.36

63.13x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Revenio Group Oyj is overvalued based on earnings compared to the GB Medical Equipment industry average.
  • Revenio Group Oyj is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Revenio Group Oyj's expected growth come at a high price?
Raw Data
BATS-CHIXE:REG1VH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 63.13x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
21.3%per year
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 2x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 517 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

BATS-CHIXE:REG1VH PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 63.13x ÷ 21.3%

2.96x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Revenio Group Oyj is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Revenio Group Oyj's assets?
Raw Data
BATS-CHIXE:REG1VH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €2.43
HLSE:REG1V Share Price * HLSE (2020-04-07) in EUR €23
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 20 Publicly-Listed Medical Equipment Companies 2.83x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,323 Publicly-Listed Companies 1.11x
BATS-CHIXE:REG1VH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= HLSE:REG1V Share Price ÷ Book Value per Share (both in EUR)

= 23 ÷ 2.43

9.47x

* Primary Listing of Revenio Group Oyj.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Revenio Group Oyj is overvalued based on assets compared to the GB Medical Equipment industry average.
X
Value checks
We assess Revenio Group Oyj's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Revenio Group Oyj has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Revenio Group Oyj expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Revenio Group Oyj expected to grow at an attractive rate?
  • Revenio Group Oyj's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Revenio Group Oyj's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • Revenio Group Oyj's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:REG1VH Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:REG1VH Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 21.3%
BATS-CHIXE:REG1VH Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 16.1%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.1%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:REG1VH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:REG1VH Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 111 38 30 1
2023-12-31 104 33 28 2
2022-12-31 89 25 23 2
2021-12-31 73 21 18 2
2020-12-31 61 14 14 2
2020-04-07
BATS-CHIXE:REG1VH Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 50 12 9
2019-09-30 43 9 8
2019-06-30 37 11 7
2019-03-31 32 9 9
2018-12-31 31 10 8
2018-09-30 30 9 8
2018-06-30 29 8 8
2018-03-31 28 8 7
2017-12-31 27 8 7
2017-09-30 26 7 7
2017-06-30 25 8 7
2017-03-31 24 7 6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Revenio Group Oyj's earnings are expected to grow significantly at over 20% yearly.
  • Revenio Group Oyj's revenue is expected to grow by 16.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:REG1VH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Revenio Group Oyj Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:REG1VH Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31 1.14 1.14 1.14 1.00
2022-12-31 0.88 0.95 0.80 2.00
2021-12-31 0.69 0.71 0.66 2.00
2020-12-31 0.53 0.53 0.52 2.00
2020-04-07
BATS-CHIXE:REG1VH Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 0.36
2019-09-30 0.32
2019-06-30 0.29
2019-03-31 0.36
2018-12-31 0.34
2018-09-30 0.32
2018-06-30 0.32
2018-03-31 0.30
2017-12-31 0.29
2017-09-30 0.30
2017-06-30 0.28
2017-03-31 0.26

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Revenio Group Oyj is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Revenio Group Oyj's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Revenio Group Oyj has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Revenio Group Oyj performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Revenio Group Oyj's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Revenio Group Oyj's year on year earnings growth rate has been positive over the past 5 years.
  • Revenio Group Oyj's 1-year earnings growth exceeds its 5-year average (15.3% vs 15.2%)
  • Revenio Group Oyj's earnings growth has exceeded the GB Medical Equipment industry average in the past year (15.3% vs -9.5%).
Earnings and Revenue History
Revenio Group Oyj's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Revenio Group Oyj Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:REG1VH Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 49.71 9.34 9.90
2019-09-30 43.36 8.02 8.44
2019-06-30 36.56 7.02 6.74
2019-03-31 32.16 8.62 5.74
2018-12-31 30.86 8.10 5.54
2018-09-30 29.81 7.65 5.30
2018-06-30 28.91 7.55 5.00
2018-03-31 28.11 7.25 4.70
2017-12-31 27.01 7.05 4.60
2017-09-30 26.00 6.85 4.73
2017-06-30 25.30 6.55 4.83
2017-03-31 24.30 6.25 4.83
2016-12-31 23.50 5.85 4.83
2016-09-30 22.20 5.07 5.21
2016-06-30 21.80 4.97 5.01
2016-03-31 20.90 4.67 4.71
2015-12-31 20.30 4.87 4.21
2015-09-30 19.84 5.31 3.33
2015-06-30 18.24 4.61 3.13
2015-03-31 16.94 4.11 2.93
2014-12-31 16.04 3.91 2.93
2014-09-30 10.11 3.15 1.29
2014-06-30 10.81 3.15 1.69
2014-03-31 10.81 3.05 1.29
2013-12-31 13.51 2.95 2.79
2013-09-30 17.93 3.67 3.96
2013-06-30 19.53 3.87 2.96

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Revenio Group Oyj has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Revenio Group Oyj used its assets more efficiently than the GB Medical Equipment industry average last year based on Return on Assets.
  • Revenio Group Oyj's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Revenio Group Oyj's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Revenio Group Oyj has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Revenio Group Oyj's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Revenio Group Oyj's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Revenio Group Oyj is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Revenio Group Oyj's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Revenio Group Oyj's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Revenio Group Oyj Company Filings, last reported 3 months ago.

BATS-CHIXE:REG1VH Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 64.36 28.08 26.68
2019-09-30 58.90 30.90 20.90
2019-06-30 55.70 32.10 20.20
2019-03-31 13.50 0.70 5.20
2018-12-31 18.07 0.32 10.38
2018-09-30 15.80 0.20 7.70
2018-06-30 13.70 0.30 4.70
2018-03-31 11.40 0.30 4.20
2017-12-31 15.99 0.34 7.95
2017-09-30 14.00 0.80 6.10
2017-06-30 12.20 0.80 4.70
2017-03-31 10.50 0.80 3.80
2016-12-31 14.97 0.75 7.08
2016-09-30 13.30 0.70 5.30
2016-06-30 11.70 0.80 3.30
2016-03-31 10.20 0.80 3.50
2015-12-31 15.03 0.91 8.32
2015-09-30 14.20 1.00 7.30
2015-06-30 12.90 1.10 6.20
2015-03-31 10.00 1.20 5.10
2014-12-31 12.06 1.38 4.11
2014-09-30 13.80 1.60 2.30
2014-06-30 15.10 1.90 2.70
2014-03-31 13.70 2.00 4.00
2013-12-31 14.96 2.00 4.60
2013-09-30 15.90 1.60 3.20
2013-06-30 15.80 1.80 4.50
  • Revenio Group Oyj's level of debt (43.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (10.5% vs 43.6% today).
  • Debt is well covered by operating cash flow (44.5%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 55.2x coverage).
X
Financial health checks
We assess Revenio Group Oyj's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Revenio Group Oyj has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Revenio Group Oyj's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.3%
Current annual income from Revenio Group Oyj dividends. Estimated to be 2.1% next year.
If you bought €2,000 of Revenio Group Oyj shares you are expected to receive €26 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Revenio Group Oyj's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.59%).
  • Revenio Group Oyj's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (7.08%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:REG1VH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.2%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 588 Stocks 5.6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.3%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.6%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:REG1VH Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.58 2.00
2021-12-31 0.48 2.00
2020-12-31 0.39 2.00
2020-04-07
BATS-CHIXE:REG1VH Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2020-02-26 0.300 1.321
2020-02-20 0.300 1.037
2019-02-25 0.280 1.344
2018-02-22 0.260 1.823
2017-03-22 0.247 2.043
2016-02-23 0.183 2.055
2015-02-24 0.150 1.942
2014-02-27 0.100 2.004
2013-03-22 0.067 2.099
2012-02-16 0.067 4.915
2011-03-31 0.067 4.168
2010-04-27 0.033 3.124
2009-08-11 0.067 5.943
2009-04-28 0.067 6.769
2009-04-08 0.067 6.313

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Revenio Group Oyj is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are stable.
  • Revenio Group Oyj is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Revenio Group Oyj's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Revenio Group Oyj's dividends as it is not paying a notable one for United Kingdom of Great Britain and Northern Ireland.
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (1.6x coverage).
X
Income/ dividend checks
We assess Revenio Group Oyj's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Revenio Group Oyj afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Revenio Group Oyj has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Revenio Group Oyj's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Timo Hildén
COMPENSATION €567,687
AGE 60
TENURE AS CEO 0.4 years
CEO Bio

Mr. Timo Hildén, M.Sc. (Econ. & Bus.Adm.), has been Chief Executive Officer of Icare Finland Oy since April 9, 2012 and is its President. Mr. Hildén serves as Acting Chief Executive Officer and President at Revenio Group Oyj since November 25, 2019. He had been President of Revenio Group Oyj ( also known as Revenio Group Corporation) since January 1, 2017 until 2019. Mr. Hildén served as Chief Executive Officer of Revenio Group Oyj since January 1, 2017 until August 5, 2019. He is Segment Director of Revenio Health Tech. He was Segment Director of Revenio Group Oyj since May 16, 2016. In the early 1990s, he was involved in the launch of production and sales companies in Russia and China, later assuming responsibility for production and marketing units in the USA, Mexico and Finland. He was also in charge of product development units in Finland and the United States. He has been a member of Revenio Group’s Management Team since May 22, 2014. He was involved in numerous acquisitions while working for Thermo. He has been a member of the board at Medisize Oy (formerly Perlos), as well as at Thermo’s Finnish subsidiary and its foreign affiliates. He was appointed CEO of Icare Finland Ltd on April 9, 2012 and has been a member of Revenio Group’s Management Team since May 22, 2014. He served as Chief Executive Officer of Revenio Research Oy. He served as the President of Thermo Labsystems Oy. Mr. Hildén served as Chief Executive Officer and Director of Global Business for liquid handling instruments at Thermo Fisher Scientific Oy. He serves as a Board Member of General Industry Federation. He has been Director of Icare Finland Oy, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy since January 1, 2017. He served as a Director at Medisize Corporation since 2008. He has worked as Revenio Group's CEO during January 1st, 2017 until July 30, 2019 as well as Revenio's Group company Icare Finland Oy's Managing Director during 2012-2017. Mr. Hildén holds an M. Sc. in Economics and Business Administration.

CEO Compensation
  • Timo's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.
  • Timo's remuneration is lower than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Revenio Group Oyj management team in years:

4.8
Average Tenure
53
Average Age
  • The tenure for the Revenio Group Oyj management team is about average.
Management Team

Timo Hildén

TITLE
Acting CEO & President
COMPENSATION
€568K
AGE
60
TENURE
0.4 yrs

Robin Pulkkinen

TITLE
Chief Financial Officer
AGE
39
TENURE
4.8 yrs

Ari Isomäki

TITLE
Operations Director
AGE
53

Tomi Karvo

TITLE
Sales & Marketing Director
AGE
53

Juha Kujala

TITLE
Secretary of the board
AGE
54
TENURE
5.9 yrs

Tiina Olkkonen

TITLE
External Communications Specialist & Secretary of Management Team
Board of Directors Tenure

Average tenure and age of the Revenio Group Oyj board of directors in years:

6.6
Average Tenure
63
Average Age
  • The tenure for the Revenio Group Oyj board of directors is about average.
Board of Directors

Pekka Rönkä

TITLE
Independent Chairman
COMPENSATION
€50K
AGE
67

Pekka Tammela

TITLE
Independent Director
COMPENSATION
€26K
AGE
57
TENURE
13 yrs

Ari Kohonen

TITLE
Independent Director
COMPENSATION
€24K
AGE
64
TENURE
7.1 yrs

Kyösti Kakkonen

TITLE
Independent Director
COMPENSATION
€24K
AGE
63
TENURE
6.1 yrs

Ann-Christine Sundell

TITLE
Independent Director
COMPENSATION
€26K
AGE
55
TENURE
4.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Revenio Group Oyj's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Revenio Group Oyj has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Revenio Group Oyj, a health technology company, designs, manufactures, and sells medical instruments for the early detection of glaucoma, diabetic retinopathy, and macular degeneration in Finland, Italy, rest of Europe, the United States, and internationally. The company offers ic100 and ic200 tonometers; Icare HOME, a device for self-measurement of eye pressure; Icare TONOVET Plus tonometers for animals; fundus imaging devices comprising EIDON, DRS, and DRSplus; MAIA, a microperimeter to measure the effectiveness of drugs for retinal disease treatment; COMPASS, which provides fundus perimetry with true-color confocal retinal images; and Ventica, to examine the variability in tidal breathing in children. It is also developing Cutica, a hyperspectral camera for dermatologists to detect skin cancers. Revenio Group Oyj is based in Vantaa, Finland.

Details
Name: Revenio Group Oyj
REG1VH
Exchange: BATS-CHIXE
Founded:
€608,329,852
26,449,124
Website: http://www.reveniogroup.fi
Address: Revenio Group Oyj
Aeyritie 22,
Vantaa,
Uusimaa, 01510,
Finland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
HLSE REG1V Ordinary Shares OMX Nordic Exchange Helsinki FI EUR 01. Oct 2001
MUN R0V Ordinary Shares Boerse Muenchen DE EUR 01. Oct 2001
LSE 0KFH Ordinary Shares London Stock Exchange GB EUR 01. Oct 2001
BATS-CHIXE REG1VH Ordinary Shares BATS 'Chi-X Europe' GB EUR 01. Oct 2001
Number of employees
Current staff
Staff numbers
120
Revenio Group Oyj employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 23:02
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/04/07
Last earnings filing: 2020/02/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.